These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

875 related articles for article (PubMed ID: 15459426)

  • 41. Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
    Henk H; Teitelbaum A; Kaura S
    Curr Med Res Opin; 2012 Jul; 28(7):1119-27. PubMed ID: 22536885
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Breast cancer: bisphosphonate therapy for metastatic bone disease.
    Body JJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6258s-6263s. PubMed ID: 17062710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
    Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
    Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer.
    Clemons M; Dranitsaris G; Cole D; Gainford MC
    Oncologist; 2006 Mar; 11(3):227-33. PubMed ID: 16549806
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Skeletal disease contributes substantially to morbidity and mortality in patients with lung cancer.
    Hirsh V
    Clin Lung Cancer; 2009 Jul; 10(4):223-9. PubMed ID: 19632938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Managing metastatic bone pain: the role of bisphosphonates.
    Gralow J; Tripathy D
    J Pain Symptom Manage; 2007 Apr; 33(4):462-72. PubMed ID: 17397707
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New research findings on zoledronic acid: survival, pain, and anti-tumour effects.
    Saad F
    Cancer Treat Rev; 2008 Apr; 34(2):183-92. PubMed ID: 18061356
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
    Terpos E; Dimopoulos MA; Berenson J
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone complications in multiple myeloma.
    Berenson JR; Rajdev L; Broder M
    Cancer Biol Ther; 2006 Sep; 5(9):1082-5. PubMed ID: 16969119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bisphosphonates in breast cancer.
    Coleman RE
    Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
    Coleman RE; Major P; Lipton A; Brown JE; Lee KA; Smith M; Saad F; Zheng M; Hei YJ; Seaman J; Cook R
    J Clin Oncol; 2005 Aug; 23(22):4925-35. PubMed ID: 15983391
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
    Body JJ
    Cancer; 2003 Feb; 97(3 Suppl):859-65. PubMed ID: 12548587
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
    Liauw W; Segelov E; Lih A; Dunleavy R; Links M; Ward R
    BMC Cancer; 2005 Jul; 5():89. PubMed ID: 16048654
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.
    Lipton A
    Cancer Treat Rev; 2008; 34 Suppl 1():S25-30. PubMed ID: 18486347
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
    Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
    Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Calcium and vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis.
    Altundag O; Altundag K; Selim Silay Y; Gunduz M; Demircan K; Gullu I
    Med Hypotheses; 2004; 63(6):1010-3. PubMed ID: 15504568
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bisphosphonates in lung cancer: more than a palliative therapy?
    Jahanzeb M; Hirsh V
    Semin Oncol; 2010 Jun; 37 Suppl 1():S45-52. PubMed ID: 20682372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.